GlassScriptPhysician profile
Marlee Pease
NPI 1114691136
$3,987.33
in general payments reported to CMS, 2019-2025
23 companies · $959 in 2025
The $959 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.89 · 2022: $1,156 · 2023: $700 · 2024: $1,124 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,199.20 | 2021-2025 | |
| Gilead Sciences, INC. | $332.06 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $269.55 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $157.10 | 2021-2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $131.02 | 2022 | |
| Qol Medical, LLC | $124.05 | 2023-2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $115.20 | 2024 | Rebyota |
| Braintree Laboratories, INC. | $82.29 | 2023-2025 | Suflave, Sutab |
| Pfizer INC. | $77.31 | 2025 | |
| Medtronic, INC. | $65.63 | 2023 | Interstim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.98 | 2022-2023 | Trulance |
| Genzyme Corporation | $55.81 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $53.17 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $50.13 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $47.41 | 2022-2025 | Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $42.48 | 2023-2024 | Idacio |
| Ardelyx, INC. | $38.02 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $21.37 | 2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $19.19 | 2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $14.22 | 2022 | |
| Lilly USA, LLC | $13.87 | 2024 | |
| Nestle Healthcare Nutrition INC. | $13.01 | 2022 | |
| Organon LLC | $9.26 | 2023 | Hadlima, Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlee Pease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.